Knowledge Translation

• (*New* 04/02/2024) CanREValue Collaboration Data Working Group Final Report 2024: Conducting Multi-Provincial Real-World Evidence Studies on Cancer Drugs
• Policy Working Groups Final Report: Developing a framework for incorporating real-world evidence into drug funding decisions. (Separate File – Report Appendix)
• (Updated 03/15/2021) Methods Working Group Interim Report: Progress Report on Real World Survival Data.
  • (03/15/2021)Responses to Stakeholder Feedback – Methods Report
• Policy Working Groups Interim Report: Developing a framework for incorporating real-world evidence into drug funding decisions. (Separate File – Report Appendix)
  • (10/30/2020) Responses to Stakeholder Feedback – Policy Report
• (Updated 04/21/2020) Data Working Group Interim Report: Mapping Canadian Provincial Data Assets to Conduct Real-World Studies on Cancer Drugs. (Separate File – Report Appendix)
  • Responses to Stakeholder Feedback – Data Report

• Issue 15, Fall 2022
• Issue 14, Spring 2022
• Issue 13, Winter 2022
• Issue 12, Fall 2021
• Issue 11, Spring 2021
• Issue 10, Fall 2020
• Issue 9, Summer 2020
• Issue 8, Spring 2020
• Issue 7, Fall 2019
• Issue 6, Summer 2019
• Issue 5, Spring 2019
• Issue 4, Fall 2018
• Issue 3, Spring 2018
• Issue 2, Winter 2018 

• 2022 Ontario Health Research Week (November 2022)
  • (On-Demand Oral) Development of a Multi-Criteria Decision Analysis (MCDA) Rating Tool to prioritize RWE questions arising from cancer drug funding decisions (Scott Gavura)
  • (On-Demand Oral) Application of the Multi-Criteria Decision Analysis (MCDA) to prioritize re-evaluations of cancer drug funding decisions (Pam Takhar)
• 2022 ASCO Quality Care Symposium (September 2022)
  • (Poster) Real-world cost effectiveness of first-line pembrolizumab for advanced melanoma: A population-based study by the Canadian Real-world Evidence Value for Cancer Drugs (CanREValue) Collaboration  (Tim Hanna)
• 2022 ARCC Conference (May 2022)
• • (On-Demand Oral) What’s in our way? The challenges and recommendations of using real-world oncology data to generate real-world evidence for drug funding decisions (Caroline Muñoz)
  • (Poster) Engaging Patients in the CanREValueInitiative: Processes and Lessons Learned (Pam Takhar)
• 2020 CADTH Symposium (November 2020)
  • (On-Demand Oral)Building a Reassessment Process for Cancer Drugs:Lessons Learned From the CanREValue Collaboration Mock Reassessment Exercise (Wei Fang Dai)
• CanREValue Stakeholder Engagement Webinar (Nov 6, 2019)
  • Slides – View a copy of the slide deck here
  • Presentation – View a recording of the webinar presentation here
• 2019 Canadian Cancer Research Conference (Nov 3-5, 2019)
  • (Oral) A Framework to Assess the Quality of RWE (Kelvin Chan)
  • (Poster) Incorporating Real World Evidence Into Cancer Drug Funding Decisions in Canada: A Qualitative Study of Stakeholders’ Perspectives (Marc Clausen)
  • (Poster) Developing a framework for the incorporation of real-world evidence into cancer drug funding decisions in Canada: An update from the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) Collaboration (Kelvin Chan)
• 2019 ARCC Conference (May 27-28, 2019)
  • (Oral) B3.2 A Reassessment Framework Developed by the CanREValue Collaborative (Alexandra Chambers)
  • (Oral) B3.3 Incorporating Real World Evidence Into Cancer Drug Funding Decisions In Canada: A Qualitative Study Of Stakeholders’ Perspectives (Marc Clausen)

• 2019 CADTH Symposium 
  • (Panel) Building the RWE Blueprint: A Coordinated Approach to RWE Use in Pharmaceutical Regulatory and Reimbursement Decisions in Canada (Panelists: Tarry Ahuja, Gayatri Jayaraman, Sylvie Bouchard, and Kelvin Chan)
  • (Oral) Incorporating Real-World Evidence into Cancer Drug Funding Decisions in Canada: A Qualitative Study of Stakeholders’ Perspectives (Marc Clausen)

• CCSN Webinar: CanREValue: Developing a framework for the incorporation of RWE into cancer drug funding decisions in Canada. (March 7, 2019, Kelvin Chan)
  • Watch Recorded Webinar

• 2018 CADTH Symposium (April 15-17, 2018)
  • (Oral) Developing a Framework for the Incorporation of Real World Evidence (RWE) into Cancer Drug Funding Decisions in Canada (Kelvin Chan)

• Development of a framework on the incorporation of real-world evidence (RWE) into cancer drug funding decisions in Canada: the Canadian Real-world Evidence for Value of Cancer
  Drugs (CanREValue) collaboration. Chan KKW, Takhar P, Evans WK, et al. BMJ Open. 2025;15:e096286. (Download)
• Real-world comparative effectiveness and safety of Pertuzumab in patients with HER2+ metastatic breast cancer: A pan-Canadian population-based cohort study. Muñoz CE, Dai WF, Cheung WY, et al. Int J Cancer. Published online April 23, 2025. doi:10.1002/ijc.35448. (Download)

• Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration. Takhar P, Geirnaert M, Gavura S, et al. Current Oncology. 2024 31(4):1876-1898. (Download)

• Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration. Parmar A, Dai WF, Dionne F, Geirnaert M, et al. Current Oncology. 2023(30):3776-3786.

• Engaging Patients in the Canadian Real-World Evidence for Value in Cancer Drugs (CanREValue) Initiative: Processes and Lessons Learned. Evans WK, Takhar P, McDonald V, et al. Current Oncology. 2022 29(8) 5616-5626.

• Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer. Dai WF, Beca JM, Nagamuthu C, et al. Jama Network Open. 2022 5(2):e2145460.
• Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer. Dai WF, Beca JM, Nagamuthu C, et al.  JAMA Oncol. 2022 Feb 24:e218049.
• Building a national reassessment process for oncology drugs: Lessons learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a simulated reassessment exercise. Dai WF, Craig E, Fraser B et al. Current Oncology. 2021 28(6), 4645-4654.

• Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group. Dai WF, Arciero V, Craig E et al. Current Oncology. 2021 28(5), 4174-4183.

• Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders’ perspectives Clausen M, Mighton C, Kiflen R et al. CMAJ Open. 2020; 8(4):E772-E778.

• Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada  Dai WF,  Beca JM, Croxford R et al. BMC Cancer. 2020; 20:304
• Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration Chan K, Nam S, Evans B et al. BMJ Open. 2020; 10:e032884
• Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer? Dai WF, Beca J, Guo H et al. Cancer Med. 2019; 00: 1– 10.

The CanREValue webpages, hosted by ARCC, are a primary means of providing public facing content. We hope you will explore and continue to revisit our site for updates in the coming years. Should you have any recommendations for content or general feedback, please email   CanREValue@cc-arcc.ca

Please visit https://cc-arcc.ca/canrevalue-resources/ for additional links and resources